SEARCH

SEARCH BY CITATION

References

  • 1
    Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis (Cochrane Review). In: The Cochrane Library. Volume 3. Chichester, UK: John Wiley & Sons Ltd., 2004.
  • 2
    Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 10531060.
  • 3
    Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 15291538.
    Direct Link:
  • 4
    Sorensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. HEPATOLOGY 2006; 44: 10751082.
  • 5
    Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297303.
  • 6
    Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 10441051.
  • 7
    Ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis: results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 17.
    Direct Link:
  • 8
    Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 2005; 21: 217226.
  • 9
    Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 10971099.
  • 10
    Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997: 3640.
  • 11
    Jick H, Terris BZ, Derby LE, Jick S. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347349.
  • 12
    Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302: 766768.
  • 13
    Hubbard R, Venn A. Adult height and cryptogenic fibrosing alveolitis: a case-control study using the UK general practice research database. Thorax 2000; 55: 864866.
  • 14
    Lewis JD, Brensinger C, Bilker WB, Strom BL. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002; 11: 211218.
  • 15
    Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 2003; 125: 15831590.
  • 16
    West J, Logan RF, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with coeliac disease: population based cohort study. Br Med J 2004; 329: 716719.
  • 17
    Solaymani-Dodaran M, Card TR, Aithal GP, West J. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 2006; 131: 17521757.
  • 18
    West J. Coeliac disease: studies of its frequency and consequence [PhD]. Nottingham: Nottingham; 2005.
  • 19
    Office for National Statistics. Mortality Statistics: Cause 2002. Series DH2 No. 29. London, UK: The Stationery Office; 2003.
  • 20
    Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2001, England. Series MB1 no. 32. London, UK: The Stationery Office; 2004.
  • 21
    Shah A, Martinez C. A comparison of the cause of death recorded in the General Practice Research Database with national mortality statistics in England and Wales. Pharmacoepidemiol Drug Saf 2004; 13: S2S3.
  • 22
    Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003; 362: 5361.
  • 23
    Floreani A, Baragiotta A, Baldo V, Menegon T, Farinati F, Naccarato R. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. HEPATOLOGY 1999; 29: 14251428.
  • 24
    Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001; 96: 11601163.
  • 25
    Shibuya A, Tanaka K, Miyakawa H, Shibata M, Takatori M, Sekiyama K, et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. HEPATOLOGY 2002; 35: 11721178.
  • 26
    Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF. Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 1999; 45: 756760.
  • 27
    Nijhawan PK, Therneau TM, Dickson ER, Boynton J, Lindor KD. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. HEPATOLOGY 1999; 29: 13961398.
  • 28
    Loof L, Adami HO, Sparen P, Danielsson A, Eriksson LS, Hultcrantz R, et al. Cancer risk in primary biliary cirrhosis: a population-based study from Sweden. HEPATOLOGY 1994; 20: 101104.